|
Biomarker efficacy in multiple sclerosis diagnosis and treatment
|
FATEMEH GHASEMI SAKHA   , SEYED MOHAMMAD MOAZZENI , FARNAZ ETESAM , AMIRREZA AZIMI SAEEN * , GHOLAMHASSAN VAEZI |
| MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran |
|
|
Abstract: (2556 Views) |
| The goal in studies concerning biomarkers in autoimmune diseases is finding a marker which fluctuates in correlation with the disease’s severity and settles within normal borders after effective treatment. This marker would later be used as an efficient tool in diagnosis and analysis of medicine clout. It seems the most cogent biomarkers are those measurable in serum or plasma. MS is a neurological disease common within the young adult population with a predictable course, often leading to life-immersing disability. The prognosis, however difficult and limited, is currently possible via diagnostic tests (brain MRI) or clinical information (severity and degrees of disability). Many studies have been conducted in an effort to detect an adequate biomarker. It is still often overlooked that a reliable biomarker should both be clinically applicable and functional is prognosis; as this is what could lead to timely treatment. |
|
| Keywords: MS biomarkers, Autoimmune disease, Demyelination, MicroRNAs |
|
|
Full-Text [PDF 342 kb]
(614 Downloads)
|
|
Article Type: Review Article |
Subject:
Neuropharmacology
|
|
|
|
|
|
